A July 2026 systematic review found only low- or very-low-certainty evidence for exosome-based nonsurgical facial rejuvenation after assessing 16 studies and 503 adults. The result shows the distance between an emerging research field and a broad anti-aging claim on a consumer product.

NAD+, stem cells and peptides create the same evidence problem in different ways. Each term names a molecule, cell type or chemical class, but none identifies a tested product, route, study population or health outcome. Those missing details determine whether published findings apply to what is being sold.

When an adverse reaction needs urgent care

The United Kingdom National Health Service says sudden swelling of the lips, mouth, tongue or throat, difficulty breathing or swallowing, fainting, or sudden confusion can signal anaphylaxis and may need immediate hospital treatment. Stop using the supplement and contact the local emergency service if these symptoms occur.

The US National Center for Complementary and Integrative Health advises people with side effects to stop taking the supplement and contact a clinician; it also says supplements can interact with medicines or create risks for some medical conditions, and many have not been tested in pregnancy, breastfeeding or children. A clinician or pharmacist needs the exact product label and medicine list to assess an individual risk.

A scientific term is not evidence for a finished product

A laboratory mechanism answers a narrow question, such as whether a molecule participates in cell signaling or whether a compound changes a blood marker. It does not establish that a packaged product slows aging in people. That claim requires a human comparison using the same ingredient, formulation and route, followed for a relevant outcome.

“Anti-aging” is not a single clinical measurement. Trials may record skin hydration, wrinkle scores, walking speed, blood chemistry or the incidence of a disease. A favorable result on one measure cannot be converted into a claim that a person is biologically younger or will live longer.

Supplement bottles marked with anti-aging and biotechnology terms (illustrative image)

Exosome evidence remains early and route-specific

Exosomes are small extracellular vesicles released by cells and studied as carriers of biological material. The word identifies a research category, not a standardized consumer ingredient. Source cells, isolation methods, contents, storage and delivery can differ, so one preparation cannot stand in for every product using the term.

A July 2026 systematic review assessed 16 nonsurgical facial-rejuvenation studies with 503 adult participants and rated the certainty of effectiveness evidence as low or very low. Most studies reported an improvement in at least one skin measure, but risk of bias was moderate to critical for most effectiveness outcomes. Inconsistent measures, short follow-up and differences between interventions prevented firm conclusions.

Those preliminary findings do not establish a benefit for every capsule, cream, gel or injection labeled “exosome.” A seller would need evidence for the actual formulation and route rather than a paper about a different preparation. Short-term reports also cannot settle uncommon or delayed harms.

Regulatory conclusions are equally product- and country-specific. In May 2025, the US Food and Drug Administration told one seller that the exosome products described in its warning letter were unapproved new drugs and unlicensed biological products under US law. That action covers the cited products and claims; it does not determine the status of every exosome-related item in the United States or another country.

NAD+ target engagement does not prove slower aging

Nicotinamide adenine dinucleotide (NAD+) is involved in cellular metabolism. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are precursors that the body can use in NAD-related pathways. Their biological role gives researchers a target to measure, but it does not establish a broad wellness outcome.

A 2026 systematic review identified 33 human intervention studies, including 28 randomized trials, and found that oral NR and NMN consistently changed circulating or cellular NAD-related markers. Functional, metabolic, vascular and other health-related outcomes were heterogeneous, often null or confined to particular endpoints. Human studies generally lasted weeks to months, leaving anti-aging effectiveness inconclusive.

The same review found no eligible outcome trials of intravenous or intramuscular NAD+ itself for anti-aging or wellness. Evidence from oral precursors therefore cannot be transferred to an infusion, and a rise in a blood marker cannot establish disease prevention, longer life or preserved independence.

A stem-cell label must identify what the product contains

A stem-cell treatment uses living stem cells or cells derived from them to replace or repair tissue. That is different from a consumer label that refers to stem cells without identifying the material, manufacturing process or route. Evidence for transplanted cells cannot support an oral or topical product with a different composition.

The International Society for Stem Cell Research said in its 2024 guide that stem-cell treatments must be evaluated for safety and efficacy in regulated clinical trials before national regulators approve them. The society also warned that some marketed interventions have not been shown to be safe or effective and, in some cases, have not even been shown to contain stem cells.

The words “stem cell” therefore do not establish identity, dose or performance. A credible claim needs a precise description of the material and a controlled human study of that same intervention for the advertised use.

Peptide and collagen claims require formulation-level evidence

“Peptide” describes a broad class of short amino-acid chains, not one intervention with a shared effect. Collagen peptides are one example, but results for a tested collagen formulation cannot prove a claim about an unrelated peptide. Digestion or detection of a peptide in blood addresses exposure rather than a visible or clinical outcome.

A 2025 meta-analysis assessed 23 randomized collagen trials with 1,474 participants and found that pooled results favored skin hydration, elasticity and wrinkles. The pattern changed when the authors separated the trials by funding and quality. Studies without pharmaceutical-company funding found no effect on those outcomes, and higher-quality studies also found no effect.

The authors concluded that current clinical evidence did not support collagen supplements for preventing or treating skin aging. That conclusion applies to the reviewed evidence and outcomes, not to every peptide product or every possible future formulation. It also shows why a favorable pooled number needs to be read alongside study quality and financial support.

An older adult examines skin in a mirror beside an anti-aging product (illustrative image)

Four details determine whether a claim matches the evidence

The first detail is identity. A report needs the exact ingredient, source, formulation and manufacturing description needed to match the commercial product with the studied intervention. An umbrella term such as exosome, peptide or stem cell is too broad for that match.

The second is route and exposure. Evidence from an injection does not establish an effect from a capsule or cream, while evidence from an oral precursor does not establish an infusion claim. The tested amount and duration also have to match, although no research dose in this report is a general recommendation.

The third is the human outcome. Animal experiments, cell studies and biomarker changes can justify further research, but a claim about wrinkles, mobility, disease or survival needs that outcome measured in people. Absolute differences, comparison groups, follow-up and withdrawals matter more than the novelty of the term.

The fourth is legal status in the market where the product is sold. A clinical paper does not authorize a product, and sale on a website does not prove authorization. APPI News could not verify the classification or authorization of exosome, NAD-related or stem-cell-labeled products in every country at the time of writing.

Evidence does not transfer to every group

Pregnancy and breastfeeding

Many dietary supplements have not been tested during pregnancy or breastfeeding, according to the US National Center for Complementary and Integrative Health. General adult studies cannot establish fetal, infant or maternal safety, so these groups need advice from a clinician familiar with the exact product.

Children

Children were not the population studied in the adult reviews cited here. Adult evidence and serving instructions cannot establish pediatric safety or benefit, and a clinician should assess any proposed use.

Chronic conditions and regular medicines

Supplements can interact with prescription or over-the-counter medicines and may pose different risks for people with medical conditions. A clinician or pharmacist needs the complete ingredient list, regular medicines and planned procedures to assess those risks.

Frequently asked questions

Does a real research term make an anti-aging claim credible?
No. The claim must match a defined product, route, population and human outcome. A laboratory mechanism or animal result can support further testing without establishing a consumer benefit.

Do NAD+ precursors reverse aging?
The 2026 review found consistent changes in NAD-related biomarkers but inconclusive effects on health and function. It did not establish longer life, disease prevention or reversal of biological aging.

Do exosome skin studies validate every exosome product?
No. The July 2026 review rated the facial-rejuvenation evidence as low or very low certainty and found substantial differences between studies. Its findings cannot be assigned to an untested capsule, cream, gel or injection.

Does “stem cell” on a label identify a stem-cell treatment?
No. A genuine cell-based intervention has a defined cell source, manufacturing process, route and regulatory pathway. A label that does not identify its material cannot borrow evidence from a different stem-cell treatment.

What makes a peptide claim testable?
The product must identify the peptide and formulation, then provide human evidence using the same route for the advertised outcome. Evidence about collagen, a blood marker or a laboratory mechanism does not establish every peptide claim.